IntrinsicIntrinsic
← All summaries

Cogent Biosciences, Inc.

COGT
Financials & Chart →

Business Summary

Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases, aiming to treat underlying causes and improve patient lives . The company's core business model revolves around the discovery, development, and potential commercialization of small molecule inhibitors for various genetically driven diseases, with a primary focus on oncology and rare diseases. Revenue generation is currently limited to funding arrangements and is expected to shift to product sales upon regulatory approval and commercial launch of its product candidates .

The company's most advanced program is bezuclastinib (CGT9486), a highly selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other KIT exon 17 mutations. This program targets Systemic Mastocytosis (SM), a rare disease driven by KIT D816V mutations, and advanced gastrointestinal stromal tumors (GIST), a type of cancer dependent on oncogenic KIT signaling . In 2025, bezuclastinib reported positive top-line results from registrational trials in Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and GIST, achieving all primary and key secondary endpoints .

For Systemic Mastocytosis, bezuclastinib is being developed for both AdvSM and NonAdvSM patients, the majority of whom have a KIT D816V mutation. The SUMMIT trial is a registration-directed Phase 2 study for moderate to severe NonAdvSM, while the APEX trial is a registration-directed Phase 2 study for AdvSM . The first New Drug Application (NDA) for bezuclastinib in NonAdvSM patients was submitted in December 2025, and an NDA for AdvSM is expected in the first half of 2026 . The FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM patients previously treated with avapritinib and in patients with Smoldering Systemic Mastocytosis (SSM) in October 2025 . Orphan drug designation has also been granted by the FDA and EMA for Mastocytosis .

In GIST, bezuclastinib is being developed in combination with sunitinib for patients who have received prior imatinib treatment. The PEAK trial, a randomized open-label global Phase 3 study, demonstrated a median Progression Free Survival (PFS) of 16.5 months for the bezuclastinib combination versus 9.2 months for sunitinib monotherapy, reducing the risk of disease progression or death by 50% . The FDA agreed to accept the NDA for bezuclastinib in combination with sunitinib for GIST under the Real-Time Oncology Review (RTOR) program in January 2026, with completion expected in April 2026 . Breakthrough Therapy Designation was also granted for this indication in January 2026, and orphan drug designation has been received from the FDA and EMA .

Beyond bezuclastinib, the company has an ongoing Phase 1 study of CGT4859, a novel internally developed FGFR2/3 inhibitor for tumors bearing FGFR2/3 mutations, including advanced cholangiocarcinoma . A Phase 1 study of CGT4255, a CNS-penetrant, selective mutant ErbB2 inhibitor for solid tumors with HER2 alterations, was initiated in the fourth quarter of 2025 . Additionally, the Cogent Research Team is developing CGT6297, a wild-type-sparing PI3Kα inhibitor, with an IND application submitted in the fourth quarter of 2025 and a Phase 1 dose escalation expected in the first quarter of 2026 . Preclinical programs include a potent and selective KRAS inhibitor and a novel, wild-type-sparing JAK2 V617F mutant-selective inhibitor, both with IND submissions planned for 2026 .

For the fiscal year ended December 31, 2025, the company reported a net loss of $328.9 million , compared to a net loss of $255.9 million in 2024 . Total operating expenses increased to $333.4 million in 2025 from $275.9 million in 2024 . Research and development expenses rose to $269.8 million in 2025 from $232.7 million in 2024 , an increase of $37.1 million . General and administrative expenses increased to $63.6 million in 2025 from $43.3 million in 2024 , primarily due to higher personnel and support costs for planned commercial launch . Interest income decreased to $14.7 million in 2025 from $18.1 million in 2024 , while interest expense was $3.1 million in 2025, up from nil in 2024 . A loss on debt extinguishment of $7.2 million was recorded in 2025, compared to nil in 2024 . As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $900.8 million , and the accumulated deficit was $1,188.4 million .

Significant operational developments in 2025 included the reporting of positive top-line results from the SUMMIT, APEX, and PEAK trials for bezuclastinib . The first NDA for bezuclastinib in NonAdvSM was submitted in December 2025 . The company initiated expanded access programs in the United States for eligible SM and GIST patients to receive investigational bezuclastinib prior to potential regulatory approval . The company also entered into a loan and security agreement for a non-dilutive term loan facility of up to $400.0 million, with a first tranche of $50.0 million funded, which was subsequently repaid in full in November 2025 . Additionally, the company completed two underwritten public offerings of common stock, generating net proceeds of approximately $215.8 million in July 2025 and approximately $324.0 million in November 2025 . A public offering of $230.0 million aggregate principal amount of 1.625% convertible senior notes due 2031 was completed in November 2025, yielding net proceeds of approximately $222.8 million .

Business Outlook

Cogent Biosciences anticipates launching bezuclastinib commercially in the United States in the second half of 2026, pending regulatory approval, for both Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST) . The company expects to complete the New Drug Application (NDA) submission for GIST in April 2026 and to submit an NDA for Advanced Systemic Mastocytosis (AdvSM) in the first half of 2026 .

A major growth area for the company is the commercialization of bezuclastinib across its target indications. Management estimates a global annual market opportunity of over $4 billion for bezuclastinib in combination with sunitinib as a potential second-line treatment for GIST patients . For Non-Advanced Systemic Mastocytosis (NonAdvSM), the estimated global annual market opportunity is approximately $3.5 billion, and for AdvSM, it is approximately $500 million . The company is building an internal commercial organization to support this launch .

Another growth vector involves expanding the pipeline of novel targeted therapies. The company expects to share clinical data from its Phase 1 study of CGT4859, a selective and potent FGFR2/3 inhibitor, in 2026 . A Phase 1 dose escalation study for CGT6297, a wild-type-sparing PI3Kα inhibitor, is expected to be initiated in the first quarter of 2026, following an IND submission in the fourth quarter of 2025 . Furthermore, IND submissions are planned for 2026 for both the KRAS inhibitor and JAK2 V617F mutant-selective inhibitor programs . In mid-2026, a Phase 2 trial is expected to be initiated to investigate the benefit of the bezuclastinib combination for first-line GIST patients with exon 9 mutations who are naive to, or recently initiated treatment with, imatinib .

Operationally, the company anticipates that its general and administrative expenses will increase in the future due to the expansion of operations to support ongoing discovery, preclinical, and clinical activities, as well as the planned commercial launch . Research and development expenses are also expected to increase substantially in connection with planned clinical and preclinical development activities . The company is building an internal commercial organization, which is expected to include up to 100 additional employees, encompassing both home office and field-based personnel .

Regarding capital allocation, the company's cash, cash equivalents, and marketable securities of $900.8 million as of December 31, 2025, are believed to be sufficient to fund operating expenses and capital expenditure requirements into 2028, including through potential FDA approval of bezuclastinib and commercial launch for SM and GIST . The company may require significant additional funding to reach profitability and to launch and commercialize any other product candidates . To raise capital, the company may sell common stock, convertible securities, or other equity securities . The company has never declared or paid cash dividends and intends to retain all available funds and future earnings for business operations .

Management has explicitly flagged several structural headwinds and execution risks. The business is highly dependent on the success of the bezuclastinib program and the ability to discover and develop additional product candidates, with no guarantee of regulatory approval or successful commercialization . The incidence and prevalence for target patient populations of drug candidates have not been established with precision, and if market opportunities are smaller than estimated or approvals are based on narrower patient definitions, revenue potential and profitability will be adversely affected . Interim, "top-line," and preliminary data from clinical trials may change, be interpreted differently, or be subject to material changes in final data . Commercial success depends on market acceptance by physicians, patients, and third-party payors, which is uncertain . Unacceptable side effects identified during development could lead to abandonment or limitation of development . The company relies on third parties for clinical trials, research, discovery, manufacturing, and supply, and their failure to perform could delay or prevent regulatory approval or commercialization . Single-source suppliers for bezuclastinib's API and drug product pose a risk, as loss of any supplier could significantly harm the business . Regulatory authorities may disagree with the regulatory plan, leading to failure to obtain approval . Evolving regulatory standards, including changes in government leadership, make it difficult to predict marketing approval likelihood .

Risk Factors

The company faces material risks including its high dependence on the bezuclastinib program and the uncertain success of developing additional product candidates . Significant competition from other biotechnology and pharmaceutical companies could adversely affect operating results if the company fails to compete effectively . The precise incidence and prevalence of target patient populations for drug candidates are not established with precision, and smaller market opportunities or narrower patient definitions could adversely affect revenue potential and profitability . Interim clinical trial data may change or be interpreted differently, potentially harming business and stock price . Commercial success of any approved drugs, including bezuclastinib, depends on market acceptance by physicians, patients, and third-party payors, which is uncertain . Unacceptable side effects identified during development could lead to abandonment or limitation of development . Reliance on third parties for clinical trials, research, discovery, manufacturing, and supply poses a risk, as their failure could delay or prevent regulatory approval or commercialization . The company's sole source of supply for bezuclastinib's API and drug product means the loss of any supplier could significantly harm the business . Regulatory authorities, including the FDA, may disagree with the regulatory plan, potentially leading to failure to obtain approval . Evolving regulatory standards, including those resulting from changes in government leadership, make it difficult to predict marketing approval likelihood . Product liability lawsuits could result in substantial liabilities and limit commercialization . Information from expanded access studies may not reliably predict efficacy in company-sponsored trials and could lead to adverse events that limit approval . Clinical trials are expensive, time-consuming, and difficult to design and implement, with a high rate of attrition . Delays in preclinical studies, clinical trials, or obtaining marketing approvals would increase product development costs . The company has incurred net losses in every year since inception, with a net loss of $328.9 million for the year ended December 31, 2025 , and anticipates continued losses, impacting stockholders' equity and working capital . Additional capital may be required, and failure to obtain it on attractive terms could delay or discontinue development and commercialization efforts . The company's ability to use net operating losses and tax credit carryforwards may be limited by ownership changes under Section 382 of the Internal Revenue Code, with approximately $73.0 million of federal and $1.5 million of state net operating losses subject to a $0.3 million per year limitation as of December 31, 2025 . Adverse legislative or regulatory tax changes, such as the 1% excise tax on stock buybacks and the amortization requirement for R&D expenditures, could negatively impact financial condition . The price of the company's stock may be volatile, and stockholders could lose all or part of their investment . Indebtedness, including $230.0 million in aggregate principal of Convertible Notes outstanding as of December 31, 2025 , could limit cash flow, expose the company to risks, and impair its ability to satisfy obligations .

Management Priorities

Management's overall tone emphasizes the company's mission to discover, develop, and commercialize best-in-class therapies for patients with genetically defined diseases, particularly focusing on the advancement of bezuclastinib. They highlight the positive top-line results from registrational trials for bezuclastinib in NonAdvSM, AdvSM, and GIST in 2025, which achieved all primary and key secondary endpoints . A key strategic priority is to advance bezuclastinib toward regulatory approval and, if approved, commercialize the product in the United States and select international markets for SM and GIST . The company expects to launch bezuclastinib commercially in the United States in the second half of 2026, pending regulatory approval . Another strategic priority is to explore the clinical utility of CGT4859, CGT4255, and CGT6297, with clinical data for CGT4859 expected in 2026, a Phase 1 study for CGT4255 initiated in Q4 2025, and a Phase 1 dose escalation for CGT6297 expected in Q1 2026 . Finally, management aims to advance its JAK2 and KRAS preclinical programs, as well as other undisclosed preclinical programs, with IND submissions planned for 2026 for both KRAS and JAK2 . The company believes its cash, cash equivalents, and marketable securities of $900.8 million as of December 31, 2025, will be sufficient to fund operating expenses and capital expenditure requirements into 2028, including through potential FDA approval of bezuclastinib and commercial launch for SM and GIST .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Financial Operations Overview
  3. [3] Item 7, MD&A — Net loss
  4. [4] Item 7, MD&A — Net loss
  5. [5] Item 7, MD&A — Total operating expenses
  6. [6] Item 7, MD&A — Research and Development Expenses
  7. [7] Item 7, MD&A — Total research and development expense increased by $37.1 million for the year ended December 31, 2025 compared to the year ended December 31, 2024.
  8. [8] Item 7, MD&A — General and Administrative Expenses
  9. [9] Item 7, MD&A — The increase in general and administrative expenses was primarily due to higher personnel and support costs due to the growth of the organization, including costs to support our planned commercial launch.
  10. [10] Item 7, MD&A — Interest Income
  11. [11] Item 7, MD&A — Interest Expense
  12. [12] Item 7, MD&A — Loss on Debt Extinguishment
  13. [13] Item 7, MD&A — Liquidity and Capital Resources
  14. [14] Item 7, MD&A — Financial Operations Overview
  15. [15] Item 7, MD&A — Liquidity and Capital Resources
  16. [16] Item 7, MD&A — Liquidity and Capital Resources
  17. [17] Item 7, MD&A — Liquidity and Capital Resources
  18. [18] Item 7, MD&A — Liquidity and Capital Resources
  19. [19] Item 7, MD&A — Overview
  20. [20] Item 7, MD&A — General and Administrative Expenses
  21. [21] Item 7, MD&A — Research and Development Expenses
  22. [22] Item 1A, Risk Factors — We have experienced significant growth and expect to continue to expand our company to support research, development and commercial capabilities and may face challenges in managing our growth.
  23. [23] Item 1A, Risk Factors — We may require additional capital to finance our planned operations. If we fail to obtain additional financing when needed, or on attractive terms, we may be unable to complete the development and commercialization of our product candidates.
  24. [24] Item 1A, Risk Factors — Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  25. [25] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
  26. [26] Item 1A, Risk Factors — Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates. We may not be successful in our efforts to develop bezuclastinib or expand our pipeline of drug candidates.
  27. [27] Item 1A, Risk Factors — The incidence and prevalence for target patient populations of our drug candidates have not been established with precision. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue potential and ability to achieve profitability will be adversely affected.
  28. [28] Item 1A, Risk Factors — Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, may be interpreted differently if additional data are disclosed, and are subject to audit and verification procedures that could result in material changes in the final data.
  29. [29] Item 1A, Risk Factors — The commercial success of any future approved drugs, including bezuclastinib, will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.
  30. [30] Item 1A, Risk Factors — If unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit such development.
  31. [31] Item 1A, Risk Factors — We currently rely and for the foreseeable future will continue to rely on third parties to conduct our clinical trials and to assist with various research, discovery, manufacturing and supply activities. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates or discover new product candidates on our intended timelines, if at all.
  32. [32] Item 1A, Risk Factors — The third parties upon whom we rely for the supply of the API and drug product used in bezuclastinib are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.
  33. [33] Item 1A, Risk Factors — Regulatory authorities, including the U.S. Food and Drug Administration (“FDA”), may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.
  34. [34] Item 1A, Risk Factors — Evolving regulatory standards, including as a result of changes in government leadership, make it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.
  35. [35] Item 1A, Risk Factors — We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  36. [36] Item 1A, Risk Factors — If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of bezuclastinib or any of our other product candidates.
  37. [37] Item 1A, Risk Factors — Information obtained from expanded access studies may not reliably predict the efficacy of our future product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval.
  38. [38] Item 1A, Risk Factors — Clinical trials are expensive, time-consuming, and difficult to design and implement.
  39. [39] Item 1A, Risk Factors — Our product development costs will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals.
  40. [40] Item 1A, Risk Factors — We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.
  41. [41] Item 1A, Risk Factors — Our ability to use net operating losses and tax credit carryforwards to offset future taxable income may be subject to certain limitations.
  42. [42] Item 1A, Risk Factors — We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
  43. [43] Item 1A, Risk Factors — The price of our stock may be volatile, and you could lose all or part of your investment.
  44. [44] Item 1A, Risk Factors — Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes.
  45. [45] Item 1A, Risk Factors — Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the notes.

Analysis on 5/20/2026